UK Report Warns Against the Use Of Puberty Blockers, Hormone Drugs for Children
The comprehensive report noted that the “rationale for early puberty suppression remains unclear”
A comprehensive report issued by an important pediatrician in the United Kingdom draws a clear warning against use of hormone drugs and puberty blockers in children.
Even as progressive politicians in the United States continue to try to normalize the use of such novel “treatments” to address what is referred to in medicine as “gender dysphoria” in children, the UK and other European countries have begun to withdraw the protocol under continued scrutiny of its safety and effectiveness.
Dr. Hilary Cass spent years reviewing existing research as well as speaking with children and families of gender dysphoric children and casts doubt on the basis for the use of such drugs for minors.
In the report, Cass notes that "The strengths and weaknesses of the evidence base on the care of children and young people are often misrepresented and overstated, both in scientific publications and social debate."
"The rationale for early puberty suppression remains unclear, with weak evidence regarding the impact on gender dysphoria, mental or psychosocial health,” she also explains. “The effect on cognitive and psychosexual development remains unknown."
The so-called Dutch protocol that employs the use of drugs to inhibit an otherwise physically healthy child’s natural development has slowly gone out of fashion in Europe, with five European countries now restricting its use with minors.
The UK’s National Health Service, which just a short time ago saw a boom in transgender-identifying teens seeking such treatment, now longer gives puberty blockers to children thanks in part to recommendations from Dr. Cass.